RevvityRVTY
RVTY
About: Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
Employees: 11,000
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
20% more call options, than puts
Call options by funds: $1.77M | Put options by funds: $1.48M
19% more repeat investments, than reductions
Existing positions increased: 191 | Existing positions reduced: 161
15% more first-time investments, than exits
New positions opened: 69 | Existing positions closed: 60
3.87% more ownership
Funds ownership: 87.62% [Q3] → 91.49% (+3.87%) [Q4]
0% more funds holding
Funds holding: 517 [Q3] → 518 (+1) [Q4]
4% less capital invested
Capital invested by funds: $13.8B [Q3] → $13.2B (-$544M) [Q4]
25% less funds holding in top 10
Funds holding in top 10: 8 [Q3] → 6 (-2) [Q4]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$102
7%
upside
Avg. target
$126
32%
upside
High target
$145
53%
upside
5 analyst ratings
4 positive
80%
1 neutral
20%
0 negative
0%
Baird Catherine Ramsey 28% 1-year accuracy 5 / 18 met price target | 34%upside $127 | Outperform Maintained | 21 Apr 2025 |
Wells Fargo Brandon Couillard 8% 1-year accuracy 2 / 25 met price target | 7%upside $102 | Equal-Weight Maintained | 17 Apr 2025 |
Barclays Luke Sergott 32% 1-year accuracy 19 / 59 met price target | 16%upside $110 | Overweight Maintained | 10 Apr 2025 |
Raymond James Andrew Cooper 24% 1-year accuracy 4 / 17 met price target | 53%upside $145 | Outperform Reiterated | 3 Feb 2025 |
Keybanc Paul Knight 11% 1-year accuracy 1 / 9 met price target | 53%upside $145 | Overweight Maintained | 3 Feb 2025 |
Financial journalist opinion
Based on 17 articles about RVTY published over the past 30 days
Positive
Zacks Investment Research
16 hours ago
RVTY Rises as Q1 Earnings & Sales Beat Estimates, '25 Sales View Up
Revvity's first-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales.
Neutral
Seeking Alpha
18 hours ago
Revvity, Inc. (RVTY) Q1 2025 Earnings Call Transcript
Revvity, Inc. (NYSE:RVTY ) Q1 2025 Earnings Conference Call April 28, 2025 8:00 AM ET Company Participants Steve Willoughby - Senior Vice President, Investor Relations Prahlad Singh - President & Chief Executive Officer Max Krakowiak - Senior Vice President & Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Dan Brennan - TD Cowen Matt Sykes - Goldman Sachs Vijay Kumar - Evercore ISI Catherine Schulte - Baird Daniel Arias - Stifel Dan Leonard - UBS Luke Sergott - Barclays Tycho Peterson - Jefferies Operator Welcome everyone to Q1 2025 Revvity Earnings Conference Call. My name is Sammy, and I will be coordinating your call today.
Neutral
Zacks Investment Research
19 hours ago
Revvity (RVTY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Positive
Benzinga
21 hours ago
Life Science Tools Maker Revvity Delivers Strong Q1 Earnings Despite Evolving Macroeconomic Backdrop
Revvity Inc. RVTY stock is trading higher on Monday after the company reported better-than-expected first-quarter 2025 earnings.
Positive
Zacks Investment Research
22 hours ago
Revvity (RVTY) Beats Q1 Earnings and Revenue Estimates
Revvity (RVTY) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $0.98 per share a year ago.
Positive
Reuters
22 hours ago
Revvity beats quarterly estimates on steady demand for medical equipment
Revvity reported first-quarter results above Wall Street estimates and maintained its full-year profit forecast on Monday, helped by steady demand from biotech clients for medical equipment used for drug research.
Neutral
Business Wire
1 day ago
Revvity Announces Financial Results for the First Quarter of 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended March 30, 2025. The Company reported GAAP earnings per share of $0.35, as compared to $0.21 in the same period a year ago. Revenue for the quarter was $665 million, as compared to $650 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $72 million, as compared to $44 million for the same period a year ago. GAAP operati.
Positive
Zacks Investment Research
3 days ago
Why Revvity (RVTY) Could Beat Earnings Estimates Again
Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Neutral
Zacks Investment Research
3 days ago
Segmental Performance to Drive RVTY's Q1 Earnings: Is a Beat Likely?
RVTY's first-quarter results are likely to reflect decent performance in the Diagnostics segment. The Life Sciences segment is likely to have faced continued challenges in China.
Neutral
Business Wire
4 days ago
Revvity Board Declares Quarterly Dividend
WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 8, 2025 to all shareholders of record at the close of business on July 18, 2025. About Revvity At Revvity, “impossible” is inspiration, and “can't be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery.
Charts implemented using Lightweight Charts™